SpineThera to Present at Discovery Square Innovators & Investors Forum

On October 10, 2017 the Mayo Clinic Center for Individualized Medicine, Destination Medical Center, and Medical Alley Association are hosting the Discovery Square Innovators + Investors Forum at the Mayo Civic Center.

Jeff Missling, CEO, will describe the value that SpineThera’s sustained-release injectable steroid, SX600, may deliver to patients, physicians, and payers. SpineThera designed SX600 with the goal of providing patients long-term back pain relief from a single epidural steroid injection.  Mr. Missling is scheduled to speak at 3:00 pm.  

About SpineThera:

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug.

About the event:

This half-day event features leaders in the healthcare and technology innovation community who are helping grow Minnesota’s healthcare economy.  Following the panel discussions and company presentations, the Investors & Innovators Reception (5:00–7:30 pm) will provide a business casual setting to connect with innovators, investors, industry executives, venture capitalists, philanthropists, key opinion leaders from academia, and key Mayo leadership to explore opportunities for collaboration.

Tagged: SpineThera, Mayo Clinic, SX600